Using clinical pathways to identify patient candidates for survivorship in testicular cancer.

• DOI: 10.1200/op.2023.19.11_suppl.492
• Publication Date: 2023-10-26T13:03:34Z
• Authors: Matthew Rice; Alex Post; Christine L. Caranfa; Trang N. Nguyen; Carly Powell; Cari Ryding; Kerry L. Kilbridge; David Michael Jac...; Alicia K. Morgans
• Keywords: Cancer survivor

492 Background: Dana-Farber Cancer Institute’s (DFCI) Clinical Pathways provide evidence-based decision support for oncologists across a variety of care settings. Data generated by enable continued cancer improvement and may also be tool identifying patient candidates survivorship. Here, we explore patients diagnosed with testicular treated curative intent. Methods: Oncologists at DFCI navigate when starting or changing therapies. Each navigation provides discrete clinical data elements about disease (e.g., histology, stage), treatment setting line therapy), selected. pathway was used to retrospectively identify who were appropriate survivorship resources. Eligibility criteria included completed therapy, had not received in 12-24 months since initial therapy navigation, follow-up appointment scheduled. Eligible referred the program. Results: Between April 2021 2022, identified 25 DFCI’s primary Longwood campus. Twelve as eligible referral. Nine those 12 (75%) successfully through survival algorithm described above. A been providers 3-remaining survivorship-eligible patients, instead EHR plan data. One screened identification process developed metastatic that captured current then deemed inappropriate The remaining 11 contacted offered As reference, total pathways usage rate between 2022 genitourinary oncology group 85% all GU malignancies, 74% cancer. Conclusions: Navigations can robust information disease, treatment. This other resources trial opportunities malignancies. impact this requires reliable provider tool.[Table: see text]